Pharmacokinetic (PK) data describing a prolonged time-course of antiretrovirals in plasma and peripheral blood mononuclear cells (PBMCs) are important for understanding and management of late or missed doses and to assess appropriateness of compounds for pre-exposure prophylaxis (PrEP). This study aimed to evaluate the PK of coformulated tenofovir DF, emtricitabine and rilpivirine in plasma and intracellular (IC) anabolites, tenofovir diphosphate (TFV-DP) and emtricitabine triphosphate (FTC-TP) in healthy volunteers up to 9 days after drug cessation. Individuals received daily tenofovir DF/emtricitabine/rilpivirine (245/200/25 mg) for 14 days. Drug intake was stopped and serial sampling occurred prior to the final dose and up to 216 hours (9 days) after stopping drug. Concentrations were quantified and PK parameters calculated. Eighteen volunteers completed the study.

 

(후략)